Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals, Inc. (CTXR) reported its fiscal Q2 2021 results, highlighting a strong balance sheet with $103.7 million in cash. The company raised approximately $96.5 million, extending its funding runway into 2023. Despite enrollment challenges in the Mino-Lok® Phase 3 trial due to COVID-19, they are on track for a Drug Monitoring Committee meeting and plan to file a New Drug Application in 2022. Citius is advancing several product candidates, including Halo-Lido and a novel stem cell therapy for ARDS, aiming to address significant medical needs.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium on May 18, 2021, at 10:30 am ET. CEO Myron Holubiak will discuss corporate strategy and key pipeline assets, including Mino-Lok®, an advanced treatment for catheter-related bloodstream infections, and NC i-MSC, a novel stem cell therapy for Acute Respiratory Distress Syndrome (ARDS), worsening due to COVID-19. Mino-Lok® is in a Phase 3 trial and has received Fast Track designation from the FDA. For registration, visit the event website.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced participation in the Benzinga Global Small Cap Conference on May 13-14, 2021. CEO Myron Holubiak will present on May 13 at 1:50 p.m. ET, focusing on the company's pipeline strategy, particularly a novel stem-cell program for treating Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. This condition currently lacks FDA-approved therapeutic options. Additionally, Citius's Mino-Lok® is undergoing a Phase 3 trial for catheter-related bloodstream infections.

Citius Pharmaceuticals (Nasdaq: CTXR) provided updates on its Mino-Lok^® Phase 3 trial during a recent webinar, highlighting the growing interest from the clinical community. Mino-Lok is an antibiotic lock therapy aimed at salvaging central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs). Currently, no FDA-approved therapies exist for this purpose. The company believes that Mino-Lok could set a new standard in treating CRBSIs, emphasizing its potential to penetrate biofilms and maintain CVC access. The FDA has granted Mino-Lok Fast Track designation.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its President and CEO, Myron Holubiak, participated in a Benzinga interview discussing the company's product pipeline, Covid-19 impact, and future milestones. The company focuses on critical care products, particularly in anti-infective treatments and stem cell therapy. Notably, its lead product, Mino-Lok®, is in a Phase III trial and has received Fast Track designation by the FDA. The interview is available on the Citius corporate website.

Citius Pharmaceuticals will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, where Executive Chairman Leonard Mazur will discuss the Phase 3 trial of Mino-Lok®, an antibiotic solution for catheter-related bloodstream infections. The trial is progressing as planned, with full enrollment expected this year. The U.S. market opportunity for Mino-Lok® is projected at $750 million, with a worldwide potential of $1.5 billion. Investors can register for the conference via the provided event website.

Citius Pharmaceuticals (Nasdaq: CTXR) will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Myron Holubiak will provide updates on the company's product pipeline, including Mino-Lok, which is in Phase 3 trials. The presentation will be accessible via webcast starting March 9 at 7:00 a.m. ET, with a replay available for 90 days. The company recently issued its February 2021 Letter to Shareholders, detailing business and clinical developments. For more information, visit the company's website.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has successfully completed a registered direct offering, raising approximately $76.5 million through the sale of 50,830,566 shares of common stock and warrants to purchase 25,415,283 shares. The offering was priced at $1.505 per share, with warrants exercisable at $1.70, valid for five years. Proceeds will support pre-clinical and clinical development, along with working capital needs. H.C. Wainwright & Co. served as the exclusive placement agent. The securities were registered under an effective SEC filing.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced a registered direct offering to sell 50,830,566 shares of common stock at $1.505 per share, along with warrants for an additional 25,415,283 shares at an exercise price of $1.70. The offering is expected to close around February 19, 2021, with gross proceeds of approximately $76.5 million. Funds will be used for general corporate purposes, including clinical development of product candidates. H.C. Wainwright & Co. is the exclusive placement agent for this offering.